Neurodegenerative Disease Market Size, Share & Growth Report by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Neurodegenerative Disease Market Size Analysis

Global Neurodegenerative Disease Market Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Multiple Sclerosis
  1. By Value
3. Parkinson's Disease
  1. By Value
4. Alzheimer's Disease
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Immunomodulator
  1. By Value
3. Vesicular Monoamine Transporter 2 (VMAT2)
  1. By Value
4. Others
  1. By Value
By Routes of Administration
1. Introduction
  1. Routes of Administration By Value
2. Oral
  1. By Value
3. Intravenous (IV) delivery
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Multiple Sclerosis
  1. By Value
3. Parkinson's Disease
  1. By Value
4. Alzheimer's Disease
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Immunomodulator
  1. By Value
3. Vesicular Monoamine Transporter 2 (VMAT2)
  1. By Value
4. Others
  1. By Value
By Routes of Administration
1. Introduction
  1. Routes of Administration By Value
2. Oral
  1. By Value
3. Intravenous (IV) delivery
  1. By Value
4. Others
  1. By Value
U.S.
1. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Multiple Sclerosis
    1. By Value
  3. Parkinson's Disease
    1. By Value
  4. Alzheimer's Disease
    1. By Value
  5. Others
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Immunomodulator
    1. By Value
  3. Vesicular Monoamine Transporter 2 (VMAT2)
    1. By Value
  4. Others
    1. By Value
3. By Routes of Administration
  1. Introduction
    1. Routes of Administration By Value
  2. Oral
    1. By Value
  3. Intravenous (IV) delivery
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Multiple Sclerosis
  1. By Value
3. Parkinson's Disease
  1. By Value
4. Alzheimer's Disease
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Immunomodulator
  1. By Value
3. Vesicular Monoamine Transporter 2 (VMAT2)
  1. By Value
4. Others
  1. By Value
By Routes of Administration
1. Introduction
  1. Routes of Administration By Value
2. Oral
  1. By Value
3. Intravenous (IV) delivery
  1. By Value
4. Others
  1. By Value
U.K.
1. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Multiple Sclerosis
    1. By Value
  3. Parkinson's Disease
    1. By Value
  4. Alzheimer's Disease
    1. By Value
  5. Others
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Immunomodulator
    1. By Value
  3. Vesicular Monoamine Transporter 2 (VMAT2)
    1. By Value
  4. Others
    1. By Value
3. By Routes of Administration
  1. Introduction
    1. Routes of Administration By Value
  2. Oral
    1. By Value
  3. Intravenous (IV) delivery
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Multiple Sclerosis
  1. By Value
3. Parkinson's Disease
  1. By Value
4. Alzheimer's Disease
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Immunomodulator
  1. By Value
3. Vesicular Monoamine Transporter 2 (VMAT2)
  1. By Value
4. Others
  1. By Value
By Routes of Administration
1. Introduction
  1. Routes of Administration By Value
2. Oral
  1. By Value
3. Intravenous (IV) delivery
  1. By Value
4. Others
  1. By Value
China
1. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Multiple Sclerosis
    1. By Value
  3. Parkinson's Disease
    1. By Value
  4. Alzheimer's Disease
    1. By Value
  5. Others
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Immunomodulator
    1. By Value
  3. Vesicular Monoamine Transporter 2 (VMAT2)
    1. By Value
  4. Others
    1. By Value
3. By Routes of Administration
  1. Introduction
    1. Routes of Administration By Value
  2. Oral
    1. By Value
  3. Intravenous (IV) delivery
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Multiple Sclerosis
  1. By Value
3. Parkinson's Disease
  1. By Value
4. Alzheimer's Disease
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Immunomodulator
  1. By Value
3. Vesicular Monoamine Transporter 2 (VMAT2)
  1. By Value
4. Others
  1. By Value
By Routes of Administration
1. Introduction
  1. Routes of Administration By Value
2. Oral
  1. By Value
3. Intravenous (IV) delivery
  1. By Value
4. Others
  1. By Value
UAE
1. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Multiple Sclerosis
    1. By Value
  3. Parkinson's Disease
    1. By Value
  4. Alzheimer's Disease
    1. By Value
  5. Others
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Immunomodulator
    1. By Value
  3. Vesicular Monoamine Transporter 2 (VMAT2)
    1. By Value
  4. Others
    1. By Value
3. By Routes of Administration
  1. Introduction
    1. Routes of Administration By Value
  2. Oral
    1. By Value
  3. Intravenous (IV) delivery
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Multiple Sclerosis
  1. By Value
3. Parkinson's Disease
  1. By Value
4. Alzheimer's Disease
  1. By Value
5. Others
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Immunomodulator
  1. By Value
3. Vesicular Monoamine Transporter 2 (VMAT2)
  1. By Value
4. Others
  1. By Value
By Routes of Administration
1. Introduction
  1. Routes of Administration By Value
2. Oral
  1. By Value
3. Intravenous (IV) delivery
  1. By Value
4. Others
  1. By Value
Brazil
1. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Multiple Sclerosis
    1. By Value
  3. Parkinson's Disease
    1. By Value
  4. Alzheimer's Disease
    1. By Value
  5. Others
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Immunomodulator
    1. By Value
  3. Vesicular Monoamine Transporter 2 (VMAT2)
    1. By Value
  4. Others
    1. By Value
3. By Routes of Administration
  1. Introduction
    1. Routes of Administration By Value
  2. Oral
    1. By Value
  3. Intravenous (IV) delivery
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Neurodegenerative Disease Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Amneal Pharmaceuticals Inc
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Hoffmann-La Roche
Boehringer Ingelheim International GmbHF
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Teva Pharmaceuticals Ltd
UCB SA
Biogen Inc
Acadia Pharmaceuticals Inc.
Neuronity Therapeutics, Inc.
Arkuda Therapeutics Inc
NeuroX1 Inc.
Annovis Bio, Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment